Showing results 151 to 170 of 174
< previous
next >
| Issue Date | Title | Author(s) |
| 2015 | Synergistic apoptotic effects of bortezomib and methylstat inhibitor on different multiple myeloma cell lines | Kacı, Fatma Necmiye |
| 2015 | Synergistic apoptotic effects of bortezomib and methylstat on different multiple myeloma cell lines | Kacı, Necmiye; Kiraz, Yağmur ; Baran, Yusuf |
| 2020 | Synergistic apoptotic effects of bortezomib and methylstat on multiple myeloma cells | Kaci, Fatma Necmiye; Kiraz, Yağmur ; Çekdemir, Demet; Baran, Yusuf |
| Jan-2017 | Synthesis, cytotoxic and antimicrobial activities of novel cobalt and zinc complexes of benzimidazole derivatives | Apohan, Elif; Yılmaz, Ülkü; Yılmaz, Özgür; Serindağ, Ayfer; Küçükbay, Hasan; Yeşilada, Özfer; Baran, Yusuf |
| Jan-2016 | T cells in tumor microenvironment | Kiraz, Yağmur ; Baran, Yusuf ; Nalbant, Ayten |
| 2009 | Targeting ceramide metabolism increased sensitivity of Philadelphia positif chronic megacaryoblastic leukemia cells to dasatinib | Gençer, Emel Başak; Ural, Ali Uğur; Avcu, Ferit; Baran, Yusuf |
| Mar-2015 | Targeting FoxM1 transcription factor in T-cell acute lymphoblastic leukemia cell line | Tüfekçi, Özlem; Kartal Yandım, Melis; Ören, Hale; İrken, Gülersu; Baran, Yusuf |
| Oct-2011 | Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation | Baran, Yusuf ; Bielawski, Jacek; Gündüz, Ufuk; Öğretmen, Besim |
| 2014 | Targeting sphingosine kinase-1/spingosine-1-phosphate receptor 2 signalling pathway to overcome T315I mutation in 32DCL3 cells | Adan Gökbulut, Aysun ; Öğretmen, Besim; Baran, Yusuf |
| Oct-2010 | Therapeutic applications of bioactive sphingolipids in hematological malignancies | Ekiz, Hüseyin Atakan ; Baran, Yusuf |
| May-2014 | Therapeutic potential of apigenin, a plant flavonoid, for imatinib-sensitive and resistant chronic myeloid leukemia cells | Solmaz, Soner; Adan Gökbulut, Aysun ; Çinçin, Zeynep Birsu; Özdoğu, Hakan; Boğa, Can; Çakmakoğlu, Bedia; Kozanoğlu, İlknur; Baran, Yusuf |
| 2015 | Therapeutic potential of fisetin and identification of its mechanisms in action in chronic myeloid leukemia and acute promyelocytic leukemia cells | Adan Gökbulut, Aysun ; Baran, Yusuf |
| 2014 | Therapeutic potential of fisetin, vitexin and hesperetin on chronic myeloid leukemia cells | Adan Gökbulut, Aysun ; Baran, Yusuf |
| 2023 | Therapeutic potential of luteolin on cancer | Çetinkaya, Melisa; Baran, Yusuf |
| Jan-2013 | Therapeutic potential of targeting ceramide/glucosylceramide pathway in cancer | Kartal Yandım, Melis; Apohan, Elif; Baran, Yusuf |
| 2010 | Therapeutic potential of targeting sphingolipid signaling pathways in various types of cancers | Baran, Yusuf ; Başsoy, Esen Yonca; Çakır, Zeynep; Camgöz, Aylin; Gencer, Emel Başak; Kartal, Melis; Can, Geylani; Ekiz, Hüseyin Atakan ; Güçlüler, Gözde |
| 2015 | Therapeutic potentials of fisetin, hesperetin and vitexin on chronic myeloid leukemia and acute myeloid leukemia cells | Adan Gökbulut, Aysun |
| 2020 | Therapeutic Potentials of Inhibition of Jumonji C Domain-containing Demethylases in Acute Myeloid Leukemia | Koca, Duygu; Hastar, Nurcan; Engür, Selin; Kiraz, Yağmur ; Ulu, Gizem Tuğçe ; Çekdemir, Demet; Baran, Yusuf |
| Dec-2015 | An update on molecular biology and drug resistance mechanisms of multiple myeloma | Mutlu, Pelin; Kiraz, Yağmur ; Gündüz, Ufuk; Baran, Yusuf |
| Jan-2014 | An update on molecular biology of thyroid cancers | Ömür, Özgür; Baran, Yusuf |
